Accordingly, high levels of CCR1 in patients with multiple myeloma have been linked to decreased overall survival [46], and increased levels of SLAMF8 mRNA have been identified as a prognosticator of worse survival in patients with high-grade gliomas [47] and colorectal cancer [48]. This evidence concerns the gene CCR1 and plasma cell myeloma.